Novartis (NVS) entered into an exclusive strategic license agreement with a clinical-stage biotechnology company, Arvinas, Inc. (ARVN) , for the worldwide development and commercialization of the latter’s pipeline candidate ARV-766. Shares of ARVN were up on the news. The deal also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis. Per the terms of the deal, Novartis will be responsible for the global development and commercialization of ARV-766. NVS will al ...